Biovitrum Enters Development Agreement with Swedish Biotech Company Synphora
Under the terms of the agreement Biovitrum will co-finance Synphora's ongoing study and, if the study is successful, also the following Phase II study with a maximum of SEK five million in total. Synphora remains fully responsible for developing JB991 up to and including clinical phase IIa. In return for the investment Biovitrum will after Phase IIa , under certain provisions, be entitled to acquire the project according to predetermined terms.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.